ATE226958T1 - Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex - Google Patents

Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex

Info

Publication number
ATE226958T1
ATE226958T1 AT94928166T AT94928166T ATE226958T1 AT E226958 T1 ATE226958 T1 AT E226958T1 AT 94928166 T AT94928166 T AT 94928166T AT 94928166 T AT94928166 T AT 94928166T AT E226958 T1 ATE226958 T1 AT E226958T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
complex
treatment
hematological disorders
Prior art date
Application number
AT94928166T
Other languages
English (en)
Inventor
Joseph A Carlino
Howard R Higley
Christopher A Maack
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE226958T1 publication Critical patent/ATE226958T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT94928166T 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex ATE226958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12441093A 1993-09-20 1993-09-20
PCT/US1994/010629 WO1995008567A1 (en) 1993-09-20 1994-09-20 Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf

Publications (1)

Publication Number Publication Date
ATE226958T1 true ATE226958T1 (de) 2002-11-15

Family

ID=22414706

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02002410T ATE297214T1 (de) 1993-09-20 1994-09-20 Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
AT94928166T ATE226958T1 (de) 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02002410T ATE297214T1 (de) 1993-09-20 1994-09-20 Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Country Status (9)

Country Link
US (1) US5527776A (de)
EP (2) EP0726911B1 (de)
JP (1) JPH09507832A (de)
AT (2) ATE297214T1 (de)
AU (1) AU688793B2 (de)
CA (1) CA2172158A1 (de)
DE (2) DE69434403T2 (de)
ES (1) ES2241906T3 (de)
WO (1) WO1995008567A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
US6468290B1 (en) 2000-06-05 2002-10-22 Scimed Life Systems, Inc. Two-planar vena cava filter with self-centering capabilities
US20030035788A1 (en) * 2000-09-19 2003-02-20 Desmond Mascarenhas Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
EP1435986B1 (de) * 2001-09-18 2008-01-02 Bioexpertise, Llc Von igf-bindungsprotein stammendes peptid
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US20050148509A1 (en) * 2003-07-09 2005-07-07 The University Of Iowa Research Foundation Binding proteins as chemotherapy
US10022212B2 (en) 2011-01-13 2018-07-17 Cook Medical Technologies Llc Temporary venous filter with anti-coagulant delivery method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
DE3852636T2 (de) * 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
DE69233155T2 (de) * 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
ATE297214T1 (de) 2005-06-15
AU688793B2 (en) 1998-03-19
CA2172158A1 (en) 1995-03-30
WO1995008567A1 (en) 1995-03-30
EP1238674A3 (de) 2002-10-23
AU7731494A (en) 1995-04-10
ES2241906T3 (es) 2005-11-01
DE69434403D1 (de) 2005-07-14
DE69431631D1 (de) 2002-12-05
DE69431631T2 (de) 2003-07-31
DE69434403T2 (de) 2006-05-04
US5527776A (en) 1996-06-18
EP0726911B1 (de) 2002-10-30
EP0726911A4 (de) 1997-02-26
EP1238674A2 (de) 2002-09-11
EP0726911A1 (de) 1996-08-21
EP1238674B1 (de) 2005-06-08
JPH09507832A (ja) 1997-08-12

Similar Documents

Publication Publication Date Title
DE69431631T2 (de) Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
GR3007092T3 (de)
ES2140463T3 (es) Prevencion y tratamiento de la neuropatia periferica.
DE68905205T2 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
GR3015490T3 (en) Composition and method for the treatment of osteoporosis in mammals.
IE871739L (en) Osteoinductive factor.
ATA105892A (de) Nagellack zur behandlung von onychomykosis enthaltend terbinafine
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
ZA89813B (en) Method for treating renal diseases
DE68907679T2 (de) Sauerwiderstehender Fibroblast-Wachstumsfaktor, Zubereitung zur Behandlung von Magen-Darmweg-Geschwürkrankheiten.
ES2174852T3 (es) Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
FI940302A (fi) Siliaarisen neurotrofisen rekombinanttifaktorin ja C-päästä lyhentyneen siliaarisen neurotrofisen faktorin puhdistus ja menetelmät perifeeristen hermovaurioiden hoitamiseksi
EP0092386A3 (en) Hydantoin therapeutic agents
ATE86497T1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties